Related Experiment Video

Updated: Mar 8, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K

Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology

Kresimir Kostovic1, Sandra J Gulin2, Zrinka B Mokos1

  • 1Department of Dermatovenereology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Salata 4, 10000 Zagreb. Croatia.

Current Medicinal Chemistry
|January 17, 2017
PubMed
Abstract

Insights

Tofacitinib, a Janus kinase inhibitor, shows promise for dermatological conditions like psoriasis and alopecia areata. However, further research is needed to balance its efficacy with safety concerns.

Area of Science:

  • Dermatology
  • Immunosuppression
  • Pharmacology

Background:

  • Tofacitinib is a novel selective immunosuppressant and Janus kinase inhibitor.
  • This review focuses on updated data regarding tofacitinib in dermatology.

Purpose of the Study:

  • To present an updated data summary on tofacitinib in dermatology.
  • To review current data on tofacitinib's properties, efficacy, and safety in dermatological indications.

Main Methods:

  • A structured search of bibliographic databases for peer-reviewed articles was conducted.
  • Inclusion criteria covered review articles, original research, and case reports.
  • Technical reports from regulatory agencies (FDA, EMA) were also included.

Main Results:

  • Forty-three papers were included in this review.
  • Data on tofacitinib's chemical properties, pharmacology, and non-clinical toxicity are reported.
  • Efficacy and safety data for psoriasis, alopecia areata, vitiligo, atopic dermatitis, and nail dystrophy were analyzed.

Conclusions:

  • The JAK/STAT pathway is crucial in the pathogenesis of several dermatological conditions.
  • Tofacitinib demonstrates encouraging efficacy in these conditions.
  • Further studies are required to establish an adequate risk-to-benefit ratio due to safety concerns.
Keywords:
CP690550JAK/STAT pathwayTofacitinibalopecia areataprotein kinase inhibitorpsoriasissmall moleculevitiligo

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Fibroblast Derived Human Engineered Connective Tissue for Screening Applications09:50

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications

Published on: August 20, 2021

4.1K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
675
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
621
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
6.0K